ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis

Navjotsingh Pabla, Shuang Huang, Qing Sheng Mi, Rene Daniel, Zheng Dong

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Cisplatin is one of the most effective anti-cancer drugs; however, the use of cisplatin is limited by its toxicity in normal tissues, particularly injury of the kidneys. The mechanisms underlying the therapeutic effects of cisplatin in cancers and side effects in normal tissues are largely unclear. Recent work has suggested a role for p53 in cisplatin-induced renal cell apoptosis and kidney injury; however, the signaling pathway leading to p53 activation and renal apoptosis is unknown. Here we demonstrate an early DNA damage response during cisplatin treatment of renal cells and tissues. Importantly, in the DNA damage response, we demonstrate a critical role for ATR, but not ATM (ataxia telangiectasia mutated) or DNA-PK (DNA-dependent protein kinase), in cisplatin-induced p53 activation and apoptosis. We show that ATR is specifically activated during cisplatin treatment and co-localizes with H2AX, forming nuclear foci at the site of DNA damage. Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53 activation and renal cell apoptosis. Consistently, cisplatin-induced p53 activation and apoptosis are suppressed in ATR-deficient fibroblasts. Downstream of ATR, both Chk1 and Chk2 are phosphorylated during cisplatin treatment in an ATR-dependent manner. Interestingly, following phosphorylation, Chk1 is degraded via the proteosomal pathway, whereas Chk2 is activated. Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis. In vivo in C57BL/6 mice, ATR and Chk2 are activated in renal tissues following cisplatin treatment. Together, the results suggest an important role for the DNA damage response mediated by ATRChk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.

Original languageEnglish (US)
Pages (from-to)6572-6583
Number of pages12
JournalJournal of Biological Chemistry
Volume283
Issue number10
DOIs
StatePublished - Mar 7 2008

Fingerprint

Cisplatin
DNA Damage
Chemical activation
Apoptosis
DNA
Kidney
Tissue
DNA-Activated Protein Kinase
Ataxia Telangiectasia
Phosphorylation
Wounds and Injuries
Therapeutic Uses
Fibroblasts
Inbred C57BL Mouse
Toxicity
Neoplasms
Genes
Cells

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. / Pabla, Navjotsingh; Huang, Shuang; Mi, Qing Sheng; Daniel, Rene; Dong, Zheng.

In: Journal of Biological Chemistry, Vol. 283, No. 10, 07.03.2008, p. 6572-6583.

Research output: Contribution to journalArticle

Pabla, Navjotsingh ; Huang, Shuang ; Mi, Qing Sheng ; Daniel, Rene ; Dong, Zheng. / ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 10. pp. 6572-6583.
@article{f46a627515664cee8fe5cb081b678b37,
title = "ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis",
abstract = "Cisplatin is one of the most effective anti-cancer drugs; however, the use of cisplatin is limited by its toxicity in normal tissues, particularly injury of the kidneys. The mechanisms underlying the therapeutic effects of cisplatin in cancers and side effects in normal tissues are largely unclear. Recent work has suggested a role for p53 in cisplatin-induced renal cell apoptosis and kidney injury; however, the signaling pathway leading to p53 activation and renal apoptosis is unknown. Here we demonstrate an early DNA damage response during cisplatin treatment of renal cells and tissues. Importantly, in the DNA damage response, we demonstrate a critical role for ATR, but not ATM (ataxia telangiectasia mutated) or DNA-PK (DNA-dependent protein kinase), in cisplatin-induced p53 activation and apoptosis. We show that ATR is specifically activated during cisplatin treatment and co-localizes with H2AX, forming nuclear foci at the site of DNA damage. Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53 activation and renal cell apoptosis. Consistently, cisplatin-induced p53 activation and apoptosis are suppressed in ATR-deficient fibroblasts. Downstream of ATR, both Chk1 and Chk2 are phosphorylated during cisplatin treatment in an ATR-dependent manner. Interestingly, following phosphorylation, Chk1 is degraded via the proteosomal pathway, whereas Chk2 is activated. Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis. In vivo in C57BL/6 mice, ATR and Chk2 are activated in renal tissues following cisplatin treatment. Together, the results suggest an important role for the DNA damage response mediated by ATRChk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.",
author = "Navjotsingh Pabla and Shuang Huang and Mi, {Qing Sheng} and Rene Daniel and Zheng Dong",
year = "2008",
month = "3",
day = "7",
doi = "10.1074/jbc.M707568200",
language = "English (US)",
volume = "283",
pages = "6572--6583",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "10",

}

TY - JOUR

T1 - ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis

AU - Pabla, Navjotsingh

AU - Huang, Shuang

AU - Mi, Qing Sheng

AU - Daniel, Rene

AU - Dong, Zheng

PY - 2008/3/7

Y1 - 2008/3/7

N2 - Cisplatin is one of the most effective anti-cancer drugs; however, the use of cisplatin is limited by its toxicity in normal tissues, particularly injury of the kidneys. The mechanisms underlying the therapeutic effects of cisplatin in cancers and side effects in normal tissues are largely unclear. Recent work has suggested a role for p53 in cisplatin-induced renal cell apoptosis and kidney injury; however, the signaling pathway leading to p53 activation and renal apoptosis is unknown. Here we demonstrate an early DNA damage response during cisplatin treatment of renal cells and tissues. Importantly, in the DNA damage response, we demonstrate a critical role for ATR, but not ATM (ataxia telangiectasia mutated) or DNA-PK (DNA-dependent protein kinase), in cisplatin-induced p53 activation and apoptosis. We show that ATR is specifically activated during cisplatin treatment and co-localizes with H2AX, forming nuclear foci at the site of DNA damage. Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53 activation and renal cell apoptosis. Consistently, cisplatin-induced p53 activation and apoptosis are suppressed in ATR-deficient fibroblasts. Downstream of ATR, both Chk1 and Chk2 are phosphorylated during cisplatin treatment in an ATR-dependent manner. Interestingly, following phosphorylation, Chk1 is degraded via the proteosomal pathway, whereas Chk2 is activated. Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis. In vivo in C57BL/6 mice, ATR and Chk2 are activated in renal tissues following cisplatin treatment. Together, the results suggest an important role for the DNA damage response mediated by ATRChk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.

AB - Cisplatin is one of the most effective anti-cancer drugs; however, the use of cisplatin is limited by its toxicity in normal tissues, particularly injury of the kidneys. The mechanisms underlying the therapeutic effects of cisplatin in cancers and side effects in normal tissues are largely unclear. Recent work has suggested a role for p53 in cisplatin-induced renal cell apoptosis and kidney injury; however, the signaling pathway leading to p53 activation and renal apoptosis is unknown. Here we demonstrate an early DNA damage response during cisplatin treatment of renal cells and tissues. Importantly, in the DNA damage response, we demonstrate a critical role for ATR, but not ATM (ataxia telangiectasia mutated) or DNA-PK (DNA-dependent protein kinase), in cisplatin-induced p53 activation and apoptosis. We show that ATR is specifically activated during cisplatin treatment and co-localizes with H2AX, forming nuclear foci at the site of DNA damage. Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53 activation and renal cell apoptosis. Consistently, cisplatin-induced p53 activation and apoptosis are suppressed in ATR-deficient fibroblasts. Downstream of ATR, both Chk1 and Chk2 are phosphorylated during cisplatin treatment in an ATR-dependent manner. Interestingly, following phosphorylation, Chk1 is degraded via the proteosomal pathway, whereas Chk2 is activated. Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates cisplatin-induced p53 activation and apoptosis. In vivo in C57BL/6 mice, ATR and Chk2 are activated in renal tissues following cisplatin treatment. Together, the results suggest an important role for the DNA damage response mediated by ATRChk2 in p53 activation and renal cell apoptosis during cisplatin nephrotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=44249118962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249118962&partnerID=8YFLogxK

U2 - 10.1074/jbc.M707568200

DO - 10.1074/jbc.M707568200

M3 - Article

C2 - 18162465

AN - SCOPUS:44249118962

VL - 283

SP - 6572

EP - 6583

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 10

ER -